Skip to content
The reference academic journal by and for the Asia-Pacific interventional cardiology community
AsiaIntervention

AsiaIntervention

  • Current Issue
  • Archives
  • How to submit
    • Authors guidelines
    • Submit your paper
  • Services
    • Advertising
    • Article reprints
    • Publication calendar
    • Rights & Permissions
  • About the journal
    • Overview
    • Editorial Board
    • Masthead
  • Contact us
Volume 8 – Number 2

Percutaneous coronary intervention in patients aged 80 years old and above: a systematic review and meta-analysis

AsiaIntervention 2022;8:123-131 | 10.4244/AIJ-D-21-00040

Norman H. Lin1, MBBS; Jamie S-Y. Ho2, MBBChir; Andie Hartanto Djohan1, MBBS, MRCP; Vanda Wen-Teng Ho3, MBBChir, MRCP; Yao Neng Teo4; Yao Hao Teo4, MBBS; Nicholas L. Syn4, MBBS; Yin Nwe Aye1, MBBS, MRCP; Rodney Y.H. Soh1, MBBS, MRCP; Tiong-Cheng Yeo1,4, MBBS, FAMS, FACC, MRCP; Hui-Wen Sim1, MBBS, MRCP; Huay-Cheem Tan1,4, MBBS, FAMS, FAsFC, FSCAI, FRCP, FACC, FAPSIC; Mark Y. Chan1,4, MBBS, MHS, MMed, PhD, MRCP; Ching-Hui Sia1,4, MBBS, EMBA, MCI, MMed, FAMS, MRCP

1. Department of Cardiology, National University Heart Centre, Singapore; 2. Academic Foundation Programme, Royal Free London NHS Foundation Trust, London, United Kingdom; 3. Division of Geriatric Medicine, University Medicine Cluster, National University Health System, Singapore; 4. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Abstract

Background: Ischaemic heart disease remains the main cause of death in the world. With increasing age, frailty and comorbidities, senior patients aged 80 years old and above who undergo percutaneous coronary intervention (PCI) are at higher risk of mortality and other complications.

Aims: We aimed to examine the overall outcomes for this group of patients.

Methods: Four databases (PUBMED, EMBASE, SCOPUS and CENTRAL) were searched. Studies with patients aged 80 years old and above who underwent PCI for all indications were included. Pooled outcomes of all-cause death, cardiac death, in-hospital death, subsequent stroke/transient ischaemic attack (TIA), subsequent myocardial infarction (MI), subsequent congestive cardiac failure (CCF), and overall major adverse cardiac events (MACE) were obtained for meta-analysis.

Results: From 2,566,004 patients, the pooled cumulative incidence of death was 19.22%, cardiac death was 7.78%, in-hospital death was 7.16%, subsequent stroke/TIA was 1.54%, subsequent MI was 3.58%, subsequent CCF was 4.74%, and MACE was 17.51%. The mortality rate of all patients was high when followed up for 3 years (33.27%). ST-elevation myocardial infarction patients had more outcomes of in-hospital death (14.24% vs 4.89%), stroke/TIA (1.93% vs 0.12%), MI (3.68 vs 1.55%) and 1-year mortality (26.16% vs 13.62%), when compared to non-ST-elevation myocardial infarction patients.

Conclusions: There was a high mortality rate at 1 year and 3 years post-PCI in the overall population of senior patients aged 80 years old and above, regardless of indication. This necessitates further studies to explore the implications of these observations.

Abbreviations

  • ACS: acute coronary syndrome
  • CABG: coronary artery bypass grafting
  • CCF: congestive cardiac failure
  • MACE: major adverse cardiac events
  • MI: myocardial infarction
  • NSTEMI: non-ST-elevation myocardial infarction
  • PCI: percutaneous coronary intervention
  • STEMI: ST-elevation myocardial infarction
  • TIA: transient ischaemic attack

Introduction

There is an increasing burden of coronary artery disease around the world1. Ischaemic heart disease remains the main cause of death globally2. With increasing age, frailty and comorbidities, senior patients aged 80 years old and above who develop ischaemic heart disease are at higher risk of mortality and other complications. Most guidelines from major cardiac societies have advocated for invasive treatment for patients who develop ischaemic heart disease, acute coronary syndromes (ACS; which include ST-elevation myocardial infarction [STEMI], non-ST-elevation myocardial infarction [NSTEMI], and unstable angina [UA])3456. However, most of these guidelines were derived from evidence that studied younger patients, as senior patients aged 80 years old and above were often underrepresented7 and, hence, less invasively managed18. The paucity of data on senior patients aged 80 years old and above has also led to major cardiac societies to call for more studies in this age group89.

To the best of our knowledge, there has been no systematic review or meta-analysis thus far that examines the overall outcomes of senior patients aged 80 years old and above undergoing percutaneous coronary intervention (PCI). Recent studies have demonstrated the benefits of an invasive approach in senior patients aged 80 years old and above. This entailed selecting them for invasive coronary angiogram, and subsequently proceeding with the appropriate management plan which included coronary artery bypass grafting (CABG), PCI, or optimal medical therapy (OMT)10. However, there are minimal studies describing the outcomes of performing PCI itself in this age group. Contemporary evidence has thus far proven survival benefits of an invasive approach in senior patients aged 80 years old and above with ACS and, to a lesser extent, morbidity benefits (in relieving anginal symptoms) in patients with stable heart disease11.

There is increased interest in the “oldest-old”, which is defined as people aged 80 years old and above, and the concept of successful ageing in this age group12131415. People in this age group are frailer, experience greater health decline, and have higher rates of hospitalisation, comorbidities and mortality. Even though they may reap the benefits of PCI in the context of ischaemic heart disease and myocardial infarction (MI), this needs to be balanced with the relative higher risk of harm from invasive interventions. Frailty not only contributes to the risk of mortality from the disease process itself but also from the intervention1617. To allow clinicians and interventionists to better manage patients in this age group, this systematic review and meta-analysis aimed to study the outcomes of PCI in senior patients aged 80 years old and above, regardless of their underlying indications (Central illustration).

Central illustration. PCI outcomes in seniors aged 80 years old and above. MACE: major adverse cardiac events; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction

Methods

Ethics approval and consent to participate was not required for this study as this study used publicly available data. We searched 4 databases (PUBMED, EMBASE, SCOPUS and CENTRAL) in February 2021, with the following search terms: “percutaneous coronary intervention” OR “PCI” OR “myocardial revasculari*” OR “coronary angioplasty” OR “percutaneous coronary revasculari*” OR “primary PCI” OR “PPCI” OR “coronary stent” OR “balloon angioplasty” OR “coronary atherectomy” AND “elderly” OR “old age” OR “octogenarian” OR “older adult” OR “older age”. We identified studies that included PCI in patients who were 80 years old and above. Studies that only included coronary angiography without the use of PCI and studies that did not include the subgroup data of PCI were excluded. We included studies with all indications for PCI, including stable coronary artery disease and ACS. Only studies published in English were included. To keep the dataset contemporary, studies with data prior to the year 2000 were excluded, as drug-eluting stents (DES) were introduced in the early 2000s. Full papers were obtained either via retrieval from the databases or by contacting the relevant authors if the papers could not be obtained from the databases. Abstracts were included if they included the relevant parameters. We included all studies, according to the population, intervention, comparison, outcome, and study design inclusion and exclusion criteria (Table 1).

Baseline characteristics included mean age, smoking history, history of hypertension, diabetes, hyperlipidaemia, stroke, atrial fibrillation, congestive cardiac failure, peripheral vascular disease, chronic kidney disease and history of PCI or CABG. We then obtained the outcomes of all-cause death, cardiac death, in-hospital death, subsequent stroke/transient ischaemic attack (TIA), subsequent MI, subsequent congestive cardiac failure (CCF) which developed as a complication of MI, and overall major adverse cardiovascular events (MACE). MACE was defined as a composite of death, stroke/TIA, MI, CCF, or revascularisation with either PCI or CABG. Data, which were reported in percentages, were converted to absolute numbers by calculation and rounded to the nearest whole number.

Statistical analysis

Extracted data were used to analyse the pooled cumulative incidence with 95% confidence intervals (CI) for outcomes of PCI. We calculated cumulative incidences utilising the 1-step generalised linear mixed-effects model (GLMM) method employing the metaprop_one routine in Stata (version 16.0; StataCorp). Compared to traditional 2-stage methods, this method is proven to produce smaller errors, less biased estimates, and greater coverage probabilities1819. When the 1-stage model failed to converge, a random-effects inverse variance-weighted meta-analysis using the Freeman-Tukey transformation was utilised to pool proportions. The random-effects model was adopted in all analyses to account for anticipated heterogeneity in the observational estimates20. Between-study heterogeneity was assessed using the I² statistic21. An I² value of <30% indicates low heterogeneity between studies, an I² of 30-60% indicates moderate heterogeneity, and an I² of >60% indicates substantial heterogeneity. A 2-sided p-value of <0.05 was considered as statistically significant. The meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Table 1)22. The various studies were appraised via the Newcastle-Ottawa scale (Supplementary Table 2, Supplementary Table 3).

Results

The PRISMA flow chart is presented in Figure 1. A literature search of the 4 databases yielded a total of 4,358 results. Three researchers were involved in the screening process (N.H. Lin, J.S-Y. Ho and C-H. Sia). A total of 4,226 articles were excluded, according to the criteria described in the flow chart, and 94 full papers and 38 abstracts were ultimately included for the analysis and discussion in this paper. The pooled data from these articles were dated from 2000 to 2018. Thirty regions (Supplementary Table 4) were represented, and common sources of studies included the USA, Japan, the UK and Italy. Sixty-two out of 132 papers reported an ACS rate of more than 50%. A summary of the baseline characteristics is described in Supplementary Table 5.

Figure 1. PRISMA flowchart. PCI: percutaneous coronary intervention

Pooled outcomes in all patients 80 years old and above

In total, we pooled 132 articles to form an overall cohort of 2,566,004 patients aged 80 years old and above in our meta-analysis, including all indications for PCI. The outcomes (Table 2) were as follows: the cumulative incidence of all-cause death (Figure 2) was 19.22% (95% CI: 16.83-21.72), cardiac death was 7.78% (95% CI: 5.53–10.85), in-hospital death was 7.16% (95% CI: 6.39-7.97), subsequent stroke/TIA was 1.54% (95% CI: 0.84-2.40), subsequent MI was 3.58% (95% CI: 2.53–4.79), subsequent CCF was 4.74% (95% CI: 2.12-10.28), and MACE was 17.51% (95% CI: 14.20-21.08). The overall follow-up period extended up to 5 years.

Figure 2. All-cause death in the overall population. CI: confidence interval; ES: effect size

One-year overall outcomes based on a pooled cohort of 36,919 patients from 52 articles and 3-year outcomes based on a pooled cohort of 6,169 patients from 9 articles demonstrated increasing rates of all-cause death (14.73% vs 33.27%), cardiac death (5.95% vs 22.81%) and subsequent CCF (4.74% vs 17.45%) over time.

Subgroup analyses

We were also able to perform a subgroup analysis of the clinical outcomes in STEMI and NSTEMI patients.

Pooled outcomes in STEMI patients

We pooled 27 articles to create a cohort of 106,343 patients who had ST-elevation myocardial infarction. In this cohort, the previous history of MI, PCI, and CABG in general (if reported) was less than 20%. The outcomes were as follows: the cumulative incidence of all-cause death was 23.08% (95% CI: 17.43-29.89), cardiac death was 9.42% (95% CI: 2.67-28.26), in-hospital death was 14.24% (95% CI: 12.09-16.53), subsequent stroke/TIA was 1.93% (95% CI: 12.09-16.53), subsequent MI was 3.68% (95% CI: 2.21-6.06), subsequent CCF was 13.08% (95% CI: 9.19-18.30), and MACE was 12.19% (95% CI: 5.11-26.35). The follow-up period extended up to 2 years, with most studies following patients up to 1 year.

Pooled outcomes in NSTEMI patients

We combined 7 articles to create a pooled cohort of 12,211 patients who had non-ST-elevation myocardial infarction. The previous history of MI was 20-40%, PCI 10%-20% and CABG 6-7% (if reported). The outcomes were as follows: the cumulative incidence of all-cause death was 14.74% (95% CI: 7.40-27.21), in-hospital death was 4.44% (95% CI: 2.65-7.36), subsequent stroke/TIA was 0.19% (0.07-0.50), subsequent MI was 1.55% (0.92-2.58), and MACE was 10.93% (95% CI: 9.79-12.18). The follow-up period extended up to 2 years, with most studies following patients up to 1 year.

STEMI patients had more outcomes than NSTEMI patients

Overall, patients with STEMI had poorer outcomes as compared to NSTEMI patients (Table 3) in the outcomes of in-hospital death (STEMI 14.24%, NSTEMI 4.89%; p-value <0.001), subsequent stroke/TIA (STEMI 1.93%, NSTEMI 0.12%; p-value <0.001), and subsequent MI (STEMI 3.68%, NSTEMI 1.55%; p-value=0.039). There were no significant differences in all-cause death (STEMI 23.08%, NSTEMI 14.74%; p-value=0.156) and MACE (STEMI 12.19%, NSTEMI 10.39%; p-value=0.809). However, 1-year outcomes showed significant differences in all-cause death between STEMI and NSTEMI patients (STEMI 26.16%, NSTEMI 13.62%; p-value <0.001) (Figure 3).

Figure 3. Three-year all-cause death in NSTEMI and STEMI populations.. CI: confidence interval; ES: effect size; FE: fixed effects;  LR: likelihood ratio; NSTEMI: non-ST-elevation myocardial infarction; RE: random effects; STEMI: ST-elevation myocardial infarction

Ischaemic time

In studies that reported ischaemic time, senior patients often had longer ischaemic times than the younger population. For example, Helft et al24 reported a median time from onset of symptoms to intervention of 251 min (versus 195 min in a younger group with a mean age of 61 years). Fach et al25 and Papapostolou et al26 reported a door-to-balloon time of 58 min (versus 43 mins in patients younger than 75 years old) and 87 min (versus 77 min in patients younger than 80 years old), respectively.

Discussion

Based on our meta-analysis, in senior patients aged 80 years old and above who underwent PCI, there was a pooled cumulative incidence of all-cause death of 18.55%, in-hospital death was at 6.7% and cardiac death was at 7.6%. There was also a 17.89% prevalence of MACE. Moreover, STEMI patients experienced a higher rate of in-hospital death, subsequent stroke/TIA and subsequent MI. The death rate was higher than that of a younger population (6.5%, mean age 59 to 65) as described in another meta-analysis of 5 studies by Stergiopoulos et al27, and similar to those previously reported by Avezum et al in the more senior age groups (18.4%, mean age 87.8)28. However, this is not unexpected as senior patients often have more comorbidities and poorer prognostic factors2829.

This high mortality rate was likely contributed to by the prevalence of underlying cardiovascular disease since most studies reported at least a 50% incidence of ACS. Other factors that have been previously quoted in other studies as contributing to the outcomes include fear of discovery of serious illnesses, atypical symptoms that mask the diagnosis of ACS (silent MI), reduced mobility that impedes access to healthcare, and economic concerns with regard to affordability of care or the lack of a dedicated caregiver30313233, all of which contribute to delayed presentations. Cognitive impairment may also mask symptom presentation34. 

Although the rate of all-cause death was 18.55%, cardiac death constituted only 7.6%, which highlights that non-cardiac causes were major contributors of death. Besides ischaemic heart disease, the next most common causes of death globally include stroke, chronic obstructive pulmonary disease and lower respiratory infections (such as pneumonia)2. In this ageing population, senior patients have more chronic diseases than younger patients, which predispose them to increased rates of mortality. Senior patients often have other concomitant illnesses such as cancer, stroke, pneumonia, as well as urinary tract infection35. These patients are frailer, have poorer myocardial reserves and, therefore, are more vulnerable to stressors and clinical insults from illnesses such as myocardial infarction36. This competing risk of death, of which frailty is a proven indicator of mortality after PCI37, may explain the relative higher proportion of death being non-cardiac in nature. 

Our analysis also demonstrated that STEMI patients had poorer outcomes as compared to NSTEMI patients. Notably, they had a higher cumulative incidence of in-hospital death (STEMI 14.24% vs NSTEMI 4.89%), stroke/TIA (STEMI 1.93% vs NSTEMI 0.12%) and MI (STEMI 3.68% vs NSTEMI 1.55%). When followed up for 1 year, they had a significantly higher rate of all-cause death (STEMI 26.16% vs NSTEMI 13.62%; p<0.001), and in-hospital death (STEMI 14.53% vs NSTEMI 7.02%). Due to the underlying pathophysiology of transmural infarct in STEMI, the effect of myocardial necrosis is more pronounced in the older age group. Senior patients with STEMI often have higher rates of post-MI complications, including various mechanical and electrical complications, leading to higher mortality rates3839. To determine the significance of the poorer 1-year adverse outcomes in STEMI patients as compared to NSTEMI patients necessitates closer follow-up in this subgroup of patients.

Longer-term 1-year and 3-year outcomes showed increasing cumulative incidences. For example, the mortality rate at 1 year was at 14.61% and 33.27% at 3 years. The 3-year outcomes were also particularly high, with a cumulative incidence of 22.81% for cardiac death, 3.54% for stroke/TIA, 5.79% for MI, 17.45% for CCF, and 14.93% for MACE. Clinicians may need to consider closer follow-up in the longer term. However, it is also important to note that the studies pooled for the 3-year outcomes included papers that compared CABG vs PCI outcomes4041, of which one study had patients with multivessel disease41, and one study had patients with left main disease42; hence, the data might have been confounded by the severe underlying disease. However, more studies are required to further explore the implications of these observations and to determine if current clinical practice is sufficient to manage the long-term outcomes of senior patients with ACS undergoing PCI. 

Although the risks of PCI in patients aged 80 years old and above were higher than in the younger population, current evidence still points towards the benefits of PCI in reducing death, cardiac death, and MI in patients with unstable coronary artery disease in the general population43. Such benefits are still seen in the senior population, mainly in the context of ACS1044. Hence, in line with most cardiac society recommendations, invasive revascularisation should still be offered to patients aged 80 years old and above with ACS, given its mortality benefit. Overall, clinicians need to appreciate the high cumulative incidence of various clinical outcomes in senior patients who have undergone PCI, taking into consideration the patient’s quality of life and goals of care, and individualise the treatment regime where appropriate.

Limitations

Our meta-analysis consisted of multiple studies examining this topic, which spanned many countries in Europe, the Middle East, and Asia. This renders our findings applicable to an ethnically diverse population. However, we acknowledge a few limitations. Most of the articles included were observational studies, and there were few randomised controlled trials. However, randomised controlled trials are difficult to perform in this population, for reasons including difficulty in obtaining informed consent and difficulty in compliance to study protocol. Also, the investigators’ concerns of potential negative trial results if senior patients are enrolled, due to their multiple comorbidities, may lead to a selection bias against senior patients. 45. Hence, they should be the continued focus of future studies. As many articles included data that crossed from the mid-2000s to the mid-2010s, we were unable to review temporal trends over the past 2 decades. As such, we were not able to exclude studies with the patients treated prior to the year 2010, and this may potentially confound our results. During this period, there was a shift towards the use of DES; hence, further studies are required to specifically examine differences between the pre-DES and DES eras. Furthermore, although frailty and sarcopenia are concepts that are gaining traction, most studies have yet to include frailty or sarcopenia in their assessment, thereby making it difficult to assess their effect on PCI outcomes. Lastly, there is variation in STEMI systems of care across various countries, and the ischaemic time was not well reported in many studies, which might have potentially affected the outcome.

Conclusions

There was a high mortality rate at 1 year and 3 years post-PCI in the overall population of senior patients aged 80 years old and above, regardless of indication. This necessitates further studies to explore the implications of these observations.

Impact on daily practice

With the increasing burden of coronary artery disease, especially in senior patients aged 80 years old and above, more studies are required to study the implications of the high mortality rate at 1 year and 3 years post-PCI, regardless of indication.

Funding

Ching-Hui Sia was supported by the National University of Singapore Yong Loo Lin School of Medicine’s Junior Academic Faculty Scheme

Conflict of interest statement

The  authors have no conflicts of interest to declare.

Share

Supplementary data

Supplementary Table 1. PRISMA checklist 2020.

Supplementary Table 2. Criteria of Newcastle-Ottawa scale.

Supplementary Table 3. Details of Newcastle-Ottawa scale.

Supplementary Table 4. Regions represented.

Supplementary Table 5. Summary of baseline characteristics.

 

References

  • Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, Alblooshi FMK, Almatrooshi MEAH, Alzaabi MEH, Al Darmaki RS, Lootah SNAH. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus 2020;12:e9349
  • World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (Last accessed 5 June 2022).
  • Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-77
  • Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289-367
  • O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425
  • Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-228
  • Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708-13
  • Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2549-69
  • Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2570-89
  • Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, Gjertsen E, Dahl-Hofseth O, Ranhoff AH, Gullestad L, Bendz B; After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty Study): an open-label randomised controlled trial. Lancet 2016;387:1057-65
  • Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini G, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 2020;382:1395-407
  • Plugge M. Successful ageing in the oldest old: objectively and subjectively measured evidence from a population-based survey in Germany. Eur J Ageing 2021;18:537-47
  • Smith J, Ryan LH. Chapter 16 – Psychological vitality in the oldest old. In: Schaie KW, Willis SL, editors. Handbook of the psychology of aging (Eighth edition). San Diego: Academic Press; 2016. p.303-19.
  • Baltes PB, Smith J. New frontiers in the future of aging: from successful aging of the young old to the dilemmas of the fourth age. Gerontology 2003;49:123-35
  • Petrová Kafková M. The " real " old age and the transition between the third and fourth age 1. Sociológia 2016;48:622-40
  • Stenvers E, Mars RC, Zuurmond RG. Frail Patients Benefit From Less Invasive Procedures. Geriatr Orthop Surg Rehabil 2019;10:2151459319885283
  • Mosquera C, Spaniolas K, Fitzgerald TL. Impact of frailty on surgical outcomes: The right patient for the right procedure. Surgery 2016;160:272-80
  • Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014;72:39
  • Lin L, Chu H. Meta-analysis of Proportions Using Generalized Linear Mixed Models. Epidemiology 2020;31:713-7
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
  • Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
  • Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021;10:89
  • Wells GA, Shea B, O’Connell Da, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Last accessed 26 February 2021).
  • Helft G, Georges JL, Mouranche X, Loyeau A, Spaulding C, Caussin C, Benamer H, Garot P, Livarek B, Teiger E, Varenne O, Monségu J, Mapouata M, Petroni T, Hammoudi N, Lambert Y, Dupas F, Laborne F, Lapostolle F, Lefort H, Juliard JM, Letarnec JY, Lamhaut L, Lebail G, Boche T, Jouven X, Bataille S; e-MUST and CARDIO-ARSIF Registries. Outcomes of primary percutaneous coronary interventions in nonagenarians with acute myocardial infarction. Int J Cardiol 2015;192:24-9
  • Fach A, Bünger S, Zabrocki R, Schmucker J, Conradi P, Garstka D, Fiehn E, Hambrecht R, Wienbergen H. Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention Analyzed by Age Groups (<75, 75 to 85, and >85 Years); (Results from the Bremen STEMI Registry). Am J Cardiol 2015;116:1802-9
  • Papapostolou S, Dinh DT, Noaman S, Biswas S, Duffy SJ, Stub D, Shaw JA, Walton A, Sharma A, Brennan A, Clark D, Freeman M, Yip T, Ajani A, Reid CM, Oqueli E, Chan W; Melbourne Interventional Group Investigators. Effect of Age on Clinical Outcomes in Elderly Patients (>80 Years) Undergoing Percutaneous Coronary Intervention: Insights From a Multi-Centre Australian PCI Registry. Heart Lung Circ 2021;30:1002-13
  • Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med 2014;174:232-40
  • Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, Eagle KA, White K, Mehta RH, Knobel E, Collet JP; GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2005;149:67-73
  • Caretta G, Passamonti E, Pedroni PN, Fadin BM, Galeazzi GL, Pirelli S. Outcomes and predictors of mortality among octogenarians and older with ST-segment elevation myocardial infarction treated with primary coronary angioplasty. Clin Cardiol 2014;37:523-9
  • Goldberg RJ, Steg PG, Sadiq I, Granger CB, Jackson EA, Budaj A, Brieger D, Avezum A, Goodman S. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol 2002;89:791-6
  • Fitzpatrick AL, Powe NR, Cooper LS, Ives DG, Robbins JA. Barriers to health care access among the elderly and who perceives them. Am J Public Health 2004;94:1788-94
  • van Gaans D, Dent E. Issues of accessibility to health services by older Australians: a review. Public Health Rev 2018;39:20
  • Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G; GRACE Investigators. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004;126:461-9
  • Taylor CA, Bouldin ED, Greenlund KJ, McGuire LC. Comorbid Chronic Conditions Among Older Adults with Subjective Cognitive Decline, United States, 2015–2017. Innov Aging 2020;4:igz045
  • Principal causes of death. Ministry of Health Singapore. https://www.moh.gov.sg/resources-statistics/singapore-health-facts/principal-causes-of-death (Last accessed 26 February 2021).
  • Frencken JF, Donker DW, Spitoni C, Koster-Brouwer ME, Soliman IW, Ong DSY, Horn J, van der Poll T, van Klei WA, Bonten MJM, Cremer OL. Myocardial Injury in Patients With Sepsis and Its Association With Long-Term Outcome. Circ Cardiovasc Qual Outcomes 2018;11:e004040
  • Murali-Krishnan R, Iqbal J, Rowe R, Hatem E, Parviz Y, Richardson J, Sultan A, Gunn J. Impact of frailty on outcomes after percutaneous coronary intervention: a prospective cohort study. Open Heart 2015;2:e000294
  • Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015;36:1163-70
  • Su PH, Chen PY, Lee SY, How CK, Chien DK, Chang WH. Comparison of clinical presentations and outcomes between adult and elderly acute myocardial infarction patients in emergency department. Health Technology. 2019;3. https://ht.amegroups.com/article/view/5325/html (Last accessed 26 February 2021).
  • Šerpytis R, Puodžiukaitė L, Petrauskas S, Misonis N, Kurminas M, Laucevičius A, Šerpytis P. Outcomes of a percutaneous coronary intervention versus coronary artery bypass grafting in octogenarians. Acta Med Litu 2018;25:132-9
  • Sheridan BC, Stearns SC, Rossi JS, D'Arcy LP, Federspiel JJ, Carey TS. Three-year outcomes of multivessel revascularization in very elderly acute coronary syndrome patients. Ann Thorac Surg 2010;89:1889-94
  • Sliman H, Jaffe R, Rubinshtein R, Karkabi B, Zissman K, Flugelman MY, Zafrir B. Clinical features and outcomes of revascularization in very old patients with left main coronary artery disease. Coron Artery Dis 2019;30:584-9
  • Chacko L, P Howard J, Rajkumar C, Nowbar AN, Kane C, Mahdi D, Foley M, Shun-Shin M, Cole G, Sen S, Al-Lamee R, Francis DP, Ahmad Y. Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes 2020;13:e006363
  • Yudi MB, Jones N, Fernando D, Clark DJ, Ramchand J, Jones E, Dakis R, Johnson D, Chan R, Islam A, Farouque O, Horrigan M. Management of Patients Aged ≥85 Years With St-Elevation Myocardial Infarction. Am J Cardiol 2016;118:44-8
  • Shenoy P, Harugeri A. Elderly patients' participation in clinical trials. Perspect Clin Res 2015;6:184-9

Volume 8 - Number 2

View full issue

Download this article
Keywords
  • ACS/NSTE-ACS
  • NSTEMI
  • STEMI
Authors
  • Andie Hartanto Djohan
  • Ching-Hui Sia
  • Huay Cheem Tan
  • Hui-Wen Sim
  • Jamie S-Y. Ho
  • Mark Y. Chan
  • Nicholas L. Syn
  • Norman H. Lin
  • Rodney Y.H. Soh
  • Tiong-Cheng Yeo
  • Vanda Wen-Teng Ho
  • Yao Hao Teo
  • Yao Neng Teo
  • Yin Nwe Aye
AsiaIntervention
  • Readers
    • Archives
    • Subscribe to the newsletter
    • Contact us
  • About the journal
    • Overview
    • Editorial Board
    • Masthead
  • Services
    • Advertising in AsiaIntervention
    • Article reprints
    • Publication calendar
    • Rights & Permissions
  • Authors
    • Authors guidelines
    • Submit your paper
  • Legal
    • Disclaimer
    • Cookies Policy
    • Privacy Policy
    • Legal Notice
  • Follow us
    • Facebook
    • Twitter
    • LinkedIn
Online ISSN 2491-0929 - Print ISSN 2426-3958
© 2015-2023 Europa Group - All rights reserved